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Induction of microhematoria by an IgA isotype switch variant of a
monoclonal anti-Thy-!.! antibody in the rat. IgA nephropathy (IgAN) is
a chronic form of glomerulonephritis (ON) characterized by the deposi-
tion in thc glomerular mesangium of mainly IgA. An experimental form of
mesangial proliferative ON can hc induced in rats by either polyclonal or
monoclonal antibodies against Thy-li, a glycoprotein present on the
surface of MC. The IgO-mediated renal inflammation is complement
dependent and associated with influx of platelets and monocytcs. Tn the
present stody we switched an lgG2a anti-Thy-li (ER4O) producing
hybridoma to an IgA anti-Thy-1.l (ER4A) producing clone and analyzed
the effects of igA anri-Thy-l.1 in rats. FPLC analysis by gel filtration
revealed that the IgA produced by the hybridoma cells was mainly dinieric
and polymeric. Infusion of rats with purified ER4A (1 mg/kg) resulted in
the deposition of IgA in a mesangial pattern in the glomeruli, similar to
that found with ER4O. While administration of ER4G resulted in
proteinuria, no significant urinary protein excretion was found in rats
treated with ER4A. However, significant mierohematuria was observed in
rats receiving either ER4A or ER4G. Furthermore, the administration of
ER4A was not accompanied by activation of complement, and no
significant influx of monoeytes or polymorphonuclear leukocytes was
observed in contrast to the rats receiving ER4G. We conclude that
mierohematuria is selectively induced in Wistar rats by mouse IgA
anti-Thy-i.l without detectable cooiplcnient-mediated injury to MC.
These studies may be of importance in understanding the mechanisms
leading to IgAN in patients.
In the kidney the glomerular mesangium is a preferential site
for immune deposit formation in patients with glomerulonephri-
tis. For example, IgA nephropathy (IgAN) and Henoch-Schitnlein
purpura (HSP) in humans are characterized by mesangial deposits
containing IgA [1, 2]. The IgA immune deposits are usually
accompanied by concomitant in situ activation of the alternative
pathway of complement as demonstrated by the co-deposition of
TgA together with C3, properdin, CSb-C9, hut not Clq or C4 [3]
and increased levels of iC3h and C3d in the circulation of these
patients 1] Furthermore, increased mesangial cell (MC) prolif-
eration and mesangial matrix-expansion are indicative of the local
inflammatory potential of locally deposited IgA 15]
Several experimental animal models have further elucidated
the pathogenic effect of lgA-eontaining deposits in the glomerular
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mesangium. Administration of preformed immune complexes
(IC) composed of polymeric mouse IgA anti-DNP and DNP-
conjugated bovine serum albumin to mice resulted in glomerular
deposition of IgA and a subsequent mesangial proliferative
response with the onset of hematuria [6].
The most extensively studied model of experimental mesangial
proliferative glomerulonephritis is the anti-thymoeyte serum
(ATS) model in which a single intravenous infusion of a poly-
elonal antibody against rat thymoeytes in adult rats results in MC
injury leading to mesangiolysis, MC proliferation and extraeellular
matrix expansion [7—9]. The Thy-l.1 antigen is a transmembrane
cell-surface glycoprotein on MC [10] and contains a glyeophos-
phatidyl-inositol (OPt) anchor [11].
Bagehus et at [12] described a unique experimental model of
glomerulonephritis (GN) in the rat that develops after a single
intravenous injection of a monoclonal anti-Thy-li antibody of
the IgO2a/ic subclass (ER4O).
Upon injection of this monoelunal antibody glomerular codepo-
sition of C3 and C5h-C9 was observed with the concomitant
activation of the congularion cascade, as reflected by fibrinogen
deposits in affected glomeruli [12—IS]. In this model of experi-
mental ON, rats develop a massive transient proteinuria reaching
average values of 300 mg/24 hr at day 3 following antibody
administration, and gradually decreasing to normal levels after
three weeks.
In a previous study we described an acute model for an
IgA-mediated glomerular inflammation after administration of
monoclonal dimerie (d-) or polymeric (p-) rat IgA antibodies to
rats [16]. Only d- and p-IgA were able to induce renal inflamma-
tion, while deposition of monomeric (m-) IgA had no effect. The
rat igA mediated inflammation was dependent on the activation
of the alternative pathway of complement and was accompanied
by influx of mononuclear cells, hypercellularity and matrix expan-
sion.
In the present study we demonstrate that an IgA class switch
variant of the ER4G anti-Thy-1.l mouse monoelonal antibody is
able to induce microhematuria in rats in the absence of detectable
activation of the complement system or significant participation of
inflammatory cells.
Methods
Materials
Chemicals were of highest quality available. (NH4)2504, gb-
taraldehyde, PBS (10 ms't sodiumphosphate, pH 7.4, 0.15 M NaCI),
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oxalic acid (Merck, Darmstadt, Germany), Tween-20 (J.T. Baker
Chemicals Co., Deventer, The Netherlands), 2,2'-amino-bis-3-
ethylbenzthiazoline-6-sulfonic acid (ABTS), bovine serum albu-
min (BSA), 2,7-diaminofluorene (DAF; Sigma Chemical Com-
pany, St. Louis, MO, USA), fluorescein isothiocyanate (FITC),
fluorescein-N-hydroxy succinimide (FNHS) and merthiolate
(Koch-light Laboratories Ltd., Colnbrook, Bucks, UK), heparin
(Organon Technica, Oss, The Netherlands), RPMI-1640 (Se-
romed Biochrom K.G., Berlin, Germany), penicillin streptomycin
(Boehringer Mannheim GmbH, Mannheim, Germany), fetal calf
serum (FCS; Gibco BrI, Grand Island, NY, USA), dispase (Col-
laborative Biochemical Products, Bedford, MA, USA), Freund's
incomplete adjuvant (Difco Laboratories, Detroit, MI, USA),
dipsticks (Hema-Combisticks, Bayer Diagnostics, Mijdrecht, The
Netherlands), goat anti-mouse IgG2a FITC and goat anti-mouse
IgA (Fe) FITC (Nordic, Tilburg, The Netherlands), rat monoclo-
nal antibodies anti-mouse IgA heavy chain, rat monoclonal anti-
bodies anti-mouse IgG2a and rat monoclonal antibody against
mousei light chain (Sanbio, Uden, The Netherlands) were ob-
tained as indicated. Mouse IgG2a monoclonal antibodies anti-
human HLA-A, B (W6/32) were obtained from American Type
Culture Collection (Rockville, MD, USA). Supernatant of trans-
genie B cells were used as a source for mouse IL-5 (a gift from Dr.
A. Rolink, Basel Institute of Immunology) [171.
Culture supernatants of human umbilical vein endothelial cells
were used as a source of IL-6 [18, 19].
The biological activity/concentration of these cytokines was
determined by their respective (bio)-assays as previously de-
scribed [17, 20, 21]. Protein A-Sepharose 4B, HiLoad 26/60
Superdex 200 prep grade were purchased from Pharmacia LKB
Biotechnology, Uppsala, Sweden.
Na '2-iodine (The Radiochemical Centre, Amersham, Bucks,
UK), Dowex (Serva, Heidelberg, Germany), lodobeads and Dc-
toxigel (Todogen; Pierce Chemical Co., Rockford, IL, USA) were
obtained as indicated.
Methods
Generation of mouse IgA anti-Thy-i.] antibodies
The generation of an TgG2a anti-Thy-l.1 producing hybridoma
clone has been reported before [12]. For the present study we
switched this mouse IgG2a producing clone (ER4G) by sequential
sublining to an IgA producing clone using an approach described
by Boot et al [22]. Balb/c mice were injected intraperitoncally
(i.p.) with 5 x 106 ER4 hybridoma cells and after development of
ascites in 6 to 8 days, ascitic fluid was collected in RPMI 1640
medium containing 50 U/ml of heparin. The cells in the ascitic
fluid were pelleted by centrifugation, resuspended in RPMI 1640
and subsequently cultured for 10 to 14 days in 96-well microtiter
plates (Greiner, Alphen a/d Rijn, The Netherlands) at a density of
100 cells/well. All supernatants were tested for the presence of
mouse IgA using a sandwich ELISA and the cells from the wells
showing a positive reaction in the IgA ELISA were collected
immediately and subcloned hy limiting dilution in RPMI 1640
containing a combination of 50 U/mI IL-6 and 10 ng/ml IL-S.
Addition of either cytokine alone failed to result in in vitro growth
of IgA switch variants. Finally, one clone (ER4A) with strong
reactivity in the mouse IgA ELISA and a negative reaction in a
mouse IgG ELISA was selected and used for the production of
IgA anti-Thy-1.1 antibodies.
Production of ER4G and ER4A anti-Thy-i.] antibodies
Ascitic fluid containing ER4A or ER4G monoclonal antibodies
was obtained from Balb/c mice which had been pretreated i.p.
with 0.5 ml Freund's incomplete adjuvant prior to inoculation i.p.
with I X 0 viable hybridoma cells. After approximately 10 days
ascitic fluid (approximately 3.5 ml per mouse) was collected from
the peritonal cavity using 19 g needles.
Detection of mouse IgA and mouse IgG
For the detection of mouse IgA, microtiter plates were coated
for two hours at 37°C with 1 j.tg of rat monoclonal anti-mouse IgA
and after washing with PBS containing 0.05% (vol/vol) Tween-20
(PBS-Tween) the wells were incubated with samples diluted in
PBS-Tween containing 1% heat inactivated FCS (vol/vol) (PBS-
Tween-FCS) and incubated for one hour at 37°C. After three
washes with PBS-Tween, bound mouse IgA was detected by
subsequent incubation for one hour with peroxidase-conjugated
rat monoclonal anti-mouse K chain antibodies (dilution 1:2000 in
PBS-Tween-FCS). After three washes the wells are filled with 100
1.d of horseradish-peroxidase substrate solution, ABTS and the
coloring reaction was stopped by adding 2% oxalic acid to each
well after 30 minutes. Optical densities were measured at 415 nm
using a Titertek Multiskan plate reader (Flow Laboratories,
Zwanenburg, The Netherlands). This ELISA is able to detect a
concentration of IgA as low as 63 ng/ml. Mouse IgG was detected
in a similar fashion except that rat monoclonal anti-mouse IgG2a
was used for the coating (dilution 1:500). The detection limit of
the mouse IgG ELISA is 94 pg/mI.
Purification of monoclonal IgA and IgG anti-Thy-I.] antibodies
Monoclonal IgA anti-Thy-1.1 and control mouse IgA anti-DNP
antibodies, MOPC3I5 [23, 24], were purified from ascitic fluid by
gel filtration column-chromatography. Briefly, ER4A or
MOPC315 ascites was collected from Balb/c mice (25 ml) and
precipitated with a final concentration of 50% (NH4)2S04, dis-
solved in 5 ml distilled water, centrifuged and the supernatant
applied to a HiLoad 26/60 Superdex 200 prep grade gel filtration
column.
Fractions of I ml each were collected and assessed for protein
content by BCA protein assay (Pierce, Rockford, IL, USA). To
test the mouse IgA content of the fractions, dilutions of 1:200 in
PBS-Tween-FCS were made and tested in the mouse IgA ELISA.
ER4G anti-Thy-1.1 and control anti-human iC3b receptor [25]
monoclonal antibodies (IB4) were purified from ascitic fluid using
a protein A Sepaharose 4B column. As in the case of ER4A,
fractions were tested for protein and mouse IgG content by BCA
protein assay and mouse lgG ELISA, respectively. Before use all
samples of IgA and IgU were passed over a 10 ml column of
Detoxi-gel for the removal of possible endotoxin contaminations.
Labeling of monoclonal IgA and IgG anti- Thy- 1.1 antibodies
ER4A was conjugated with FNHS according to the instructions
of the manufacturer. In brief, 9 mg/mI of ER4A in PBS was mixed
with FNHS at a relative molecular ratio (ER4A:FNHS = 1:10).
followed by incubation for 90 minutes on ice. Free FNHS was
separated from FNHS-Iabeled ER4A by using a Centricon-30
cartridge (Amicon Inc., MA, USA) and extensive washing with
phosphate buffer.
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Purified mouse monoclonals (ER4A, ER4G, MOPC3L5 and
W6/32) were radiolaheled with '25iodine using lodoheads accord-
ing to the manufacturer's instructions to specific activities of I
xCi/jsg of protein. Protein-bound iodine was separated from free
iodine by Dowex cation exchange chromatography.
Binding of ER4 antibodies to cultured rat MC
In vitro binding of ER4A and ER4G to rat MC was studied as
follows: rat MC were obtained as described previously [26 and
used between passages five to ten. To assess the binding of each
purified monoclonal antibody, a defined number of cells was
subcultured to confluency in flat bottom 96-well microtitcr plates
containing RPM! 1640 with 10% FCS. After washing with PBS,
the cells were fixed by adding 100 jxl of PBS containing 0.1%
glutaraldehyde and incubated on ice for ten minutes. Subse-
quently the cells were washed three times with PBS and the wells
were preincubated with 101) M1 per well of PBS containing 1%
BSA (PBS-BSA) for one hour at 37°C. Following a wash serial
dilutions of ER4A or ER4G in PBS-Tween-FCS (starting at it)
isg/ml and 2 J.Lg/ml, respectively) were added to the wells in
duplicate and the plates were incubated for one hour at 37°C.
Bound antibodies were detected by subsequent incubation for one
hour at 37°C with peroxidase-conjugated goat anti-mouse lgG2a
or goat anti-mouse IgA (Fe) antibodies (dilution 1:1600 and
1:1000 in PBS-Tween-BSA, respectively).
After three washes the wells were filled with 100 gI of horse-
radish-peroxidase substrate solution, ABTS and the coloring
reaction was stopped by adding 2% oxalic acid to each well after
30 minutes. Optical densities were measured at 415 nm using a
Titertek Multiskan plate reader and results are expressed accord-
ingly.
FA CS analysis
Confluent MC in T75 culture flasks were washed with PBS and
subsequently detached with 2 ml dispase j26] at 37°C for thirty
minutes. The cells were collected in PBS containing 10% FCS
(PBS-FCS), to inactivate the dispase, and washed twice with
PBS-FCS. After resuspension in PBS containing 1% BSA (PBS-
BSA), the cells were distributed at a density of I >< l0 cells per
tube. To determine the specificity of binding of ER4A to rat MC,
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01
MC were incubated with 0.9 .rg of FNI-1S-conjugated ER4A in the
presence of increasing concentrations of unlabeled ER4A or
ER4G for 30 minutes on ice. After washing with PBS-BSA, MC
were fixed with 1% paraformaldehyde and FNHS-ER4A binding
was assessed by FACS (Beeton Dickinson). The results were then
expressed as % inhibition of binding of FNHS-ER4A to MC and
resulted in 90.5% positivity for FNHS-ER4A. At least 5,000 cells
from each sample were analyzed.
Quantification of kidney-bound monoclonal igA and IgG anti-
Thy-i. I antibodies
To determine the amount of ER4A and ER4G bound to the
kidney twelve male Wistar rats (N = 3 for each group) each
received a 1 mg/kg body wt intravenous (i.v.) injection of 125j
labeled monoclonal antibody.
After two hours the kidneys were perfused with 100 ml of PBS
and assessed for total kidney bound radioactivity. To determine
the non-specific trapping in the kidney '251-labcled controls,
MOPC315 and W6/32 were used. The amount of specifically
bound radioactivity was finally calculated.
In vivo experiments
inbred female Wistar rats, weighing approximately 150 grams
were divided into three groups of five rats each. One group of rats
received an i.v. injection of 1 mg/kg body wt of ER4G in saline at
day 0; the second group received an i.v. injection of 1 mg/kg body
wt of the ER4A (peak 2, 30t) kDa; Fig. 1) switch variant in saline
and the third group of rats received an i.v. injection of an equal
volume of PBS alone.
Twenty-four hour urine was collected before the injections, on
day one and during the course of the experiment. In addition
kidney biopsies were taken of all rats before the start of the
experiment, on day 1 and day 6. The rats were sacrificed on day 6.
Kidney biopsies were split in two; one half was used for immuno-
fluorescence and the other half processed for light microscopy.
Histolo and immunofluorescence
Renal tissue specimen (4 mm2) were fixed in 4% buffered
formalin, paraffin embedded, sectioned and stained with periodic
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Fig. 1. Size analysis of ER4A anti-Thy-I. I
antibodies on 1-f R200. The molecular weight
markers, thyroglobulin (669 kDa), apoferritin
(443 kDa), -amylase (200 kDa), alcohol
dehydrogenase (150 kDa) and albumin (60
kfla) are indicated. Symbols are: (S) IgA; (0)
protein.
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Photographs were taken on Kodak TX-400 film on a Leitz
microscope equipped with a 4 mm BG 38 + 5 mm BG 12 filter for
FITC.
Proteinuria and hematuria
The rats were housed in metabolic cages throughout the course
of the experiment. Protein excretion was determined daily in
24-hour urine samples containing 0.1% merthiolate by the biuret
method using rat serum albumin as a protein standard.
Hematuria was assessed by staining sectioned paraffin-embed-
ded rat kidney slides with hematoxylin-eosiri (H&E) followed by
scoring a complete kidney tissue cross-section for erythrocytes in
the lumen of renal tubules. Each tissue sample was evaluated in a
blinded fashion using coded slides.
Hematuria was also determined by both dipsticks and direct
microscopic enumeration of erythrocytes in full urine.
Erythrocytes in three random x400 microscopic fields from
each of five separate urine samples were counted. In addition a
colorimetric method for the detection of hemoglobin with DAF
was used [311. The sensitivity of this assay using fresh rat
erythrocytes as a standard was 5,000 red blood cells (RBC) per ml.
Results
Monoclonal IgG2a and IgA antibodies against Thy-1.1
The ER4G IgG2a-producing hybridoma was switched to an IgA
producing clone by in vivo passage and subsequent in vitro culture
in cytokinc-containing media (The IgG2a clone will be indicated
as ER4G and the IgA switch variant by ER4A). Ascites was
produced in mice and assessed for class specificity by staining
normal renal sections of rats. The ER4G ascites only gave positive
mesangial staining for IgG2a and not for IgA. The ER4A clone
revealed a positive reaction, identical in staining pattern to the
ER4G, for IgA alone and not for IgO (data not shown).
Next, we assessed the molecular size of the ER4A antibody by
gel filtration on HR200. IgA reactivity in the fractions was found
in three peaks: 450, 300 and 150 kDa (Fig. 1). The first peak
represents polymeric IgA, the second peak dimeric IgA and the
third small peak monomeric IgA. This indicated that hybridoma
ER4A predominantly secreted polymeric IgA. The ER4G when
analyzed by l-1R200 gel filtration revealed only one peak of 150
kDa (data not shown).
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Fig. 3. Urinaiy protein excretion monitored for six days in rats treated with(0) PBS, (•) ER4A or () ER4G. Mean values of 5 rats SI) are
depicted.
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Fig. 2. FACS analysis of inhibition of binding of FNHS-labeled ER4A to rat
MC by nonlabeled ER4A and ER4G. Symbols are: (0) ER4G; (•) ER4A;
(A) 1B4; (A) MOPC315.
acid-Schiff (PAS) or hematoxylin-eosin (H&E). In each kidney
specimen at least 100 glomeruli were selected at random and
evaluated by light-microscopy.
Kidney specimen were processed for immunofluorcscence (IF)
according to standard procedures. Briefly, rat renal tissue was
snap-frozen in pre-cooled iso-butanol and stored at —80°C or in
liquid nitrogen. Cryostat sections of 2 /xm were obtained and after
air-drying, fixed in acetone for 10 minutes at room temperature
(RT).
The slides were washed twice for seven minutes in PBS and
examined for the presence of mouse IgA, mouse IgG, rat C3 and
infiltration of monocytes/macrophages in the glomeruli by using
FITC-conjugated goat anti-mouse IgA (F/P ratio 2; 1 mg/mI;
dilution 1:50), FITC-conjugated goat anti-mouse IgG2a (F/P ratio
2; 1 mg/mI; dilution 1:100), and FITC-conjugated rabbit anti-rat
C3 (F/P ratio 2.6; 5 mg/mI; dilution 1:100).
Macrophages were detected with FITC-conjugated mouse
monoclonal anti-rat macrophage antibody, ED-I (provided by Dr.
C.D. Dijkstra, Free University of Amsterdam, Amsterdam, The
Netherlands) (F/P ratio 3.3; 1.3 mg/mI; dilution 1:50) [271.
The glomerular influx of macrophages was determined by
counting the total number of macrophages in at least twenty
glomerular cross-sections per rat and expressed as the average
number of macrophages per glomerulus.
The influx of glomerular polymorphonuclear cells (PMN) was
determined with FITC-laheled monoclonal antibody W3/1 3 (F/P
ratio 2.4; 1.95 mg/mI; dilution 1:50). Between the one hour
incubation steps at RT the slides were washed three times for
seven minutes with PBS at RT.
Proliferating cells in rat glomeruli were detected by staining for
the proliferating cell nuclear antigen (PCNA/cyclin). PCNA/cyclin
is an auxiliary protein to b-I)NA polymerase; its expression is
restricted to late Gi, S, G2 and M phases of the cell-cycle [28-301.
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Fig. 4. Immunofluorescence staining fhr mouse IgG2a and mouse IgA in glomeruli of rats before the injection (day 0), and on day I and day 6 after injection
of ER4G or ER4A (All, X250).
By cell ELISA in which rat MC in monolayers were incubated
with dose responses of ER4G or ER4A a dose-dependent binding
of ER4A and ER4G was found. Furthermore, specific binding of
both anti-Thy-i.! isotypes to MC in suspension occurred with
both ER4A and ER4G as assessed by FACS. Controls of MC with
conjugate alone revealed less than 2 and 5% positive cells,
respectively. In addition controls, 1B4 and MOPC315 revealed
only less than 1.6% and 3.3% positive cells, respectively. To
further demonstrate clonality and unaltered epitope specificity of
the IgA switch variant a reciprocal inhibition analysis of FNHS-
labeled ER4A by non-labeled ER4A and ER4G was performed
(Fig. 2). Both unlabeled ER4A and ER4G were able to inhibit the
binding of FNHS-labeled ER4A to MC in a dose-dependent
fashion up to 90%. However ER4G was 100 times more efficient
as compared to ER4A in prevention of binding of FNHS-labeled
ER4A to MC. Control mouse IgG or mouse IgA only induced a
marginal inhibition of binding of FNHS-labeled ER4A at concen-
trations of maximal input.
Four batches of aseitie fluid of ER4A were produced, all
containing IgA antibodies with Thy-1.1 specificity and a concen-
tration of IgA as assessed by radial immunodiffusion of 0.85 0.2
mg/mi ascites. No difference of in vivo effects between the four
batches of ER4A were observed.
To further assess the amount of ER4G and ER4A that hound
to the kidneys two hours following Lv. administration, rats were
injected with '251-laheled ER4A or ER4G. Following administra-
tion of 1 mg/kg body wt radiolabeled monoclonal antibodies,
6.7 1.9 jig of ER4G and 1.2 0.2 jig of ER4A were bound
specifically to one rat kidney. The binding of control mouse !gG2a
or mouse IgA (W6/32 and MOPC315, respectively) to the kidneys
was negligible.
Effocts of ER4G and ER4A in vivo
Groups of rats were injected either with 1 mg/kg body wt of
purified ER4G, 1 mg/kg body wt of ER4A or PBS intravenously.
Urine was collected before injection and during the course of the
experiment.
Administration of ER4G resulted in proteinuria which reached
its maximum at day 3 (Fig. 3) and remained at a plateau level until
day 5 after which a slight decrease was seen. No abnormal
proteinuria was found in the rats injected with ER4A or PBS.
When the kidney biopsies of the rats were analyzed for the
presence of IgG or IgA, the animals injected with the ER4G
revealed a positive mesangial staining with anti-IgG and the rats
receiving ER4A a positive reaction with anti-IgA at day 1. At days
2 and 5 after injection less IgA was observed as compared to day
I (data not shown). At day 6 a reduced staining for both lgG or
IgA was seen (Fig. 4).
No mesangial deposition of rat IgG or 1gM was detected by
indirect immunofluorescence in the biopsies of ER4A and ER4G
treated rats on days I and 6 (not shown).
When the biopsies of the rats were analyzed for histological
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Fig. 5. Light microscopy of rat kidney sections before injection (day 0), and on day I and day 6 after treatment wit/i ER4A or ER4G (PAS staming, )<400).
Matrix expansion is seen on day 6 in a glomerulus of a rat injected with ER4G (indicated by arrow).
abnormalities, the ER4G receiving animals revealed MC lysis,
mesangial proliferation, mesangial matrix expansion and microa-
neurysms on day 6. Interestingly, the animals receiving IgA only
transiently exhibited slightly disrupted mesangial matrices with
small open areas on day 1, while no significant abnormalities were
observed on day 6 (Fig. 5).
Because no detectable proteinuria (Fig. 3) and no severe
abnormalities were seen in the animals injected with ER4A, the
biopsies were also analyzed for deposition of C3 and influx of
inflammatory cells.
While the ER4G receiving rats showed a clear mesangial
deposition of C3, the ER4A rats were essentially negative (Fig. 6
a, b). In ER4G rats a transient influx was observed of monocytes
and PMN on day I (Fig. 6 d, g), which was virtually absent in
ER4A injected rats (Fig. 6 e, h).
In the case of IgA no significant influx of neither monocytes nor
PMN was observed. The influx of monocytes was quantified and
revealed that on day 1 ER4G receiving rats had an average of 4.2
monocytes per glomerular cross section. This increase in number
of macrophagcs was significant (P < 0.05), while the ER4A or
control rats did not show any change in the number of ED1
positive cells (Table 1). The ER4G rats showed normal numbers
of inflammatory cells again on day 6.
We also analyzed the proliferation of MC in the glomcruli in
the three groups of rats by PCNA staining. Control rats had 0.5
0,7 proliferating cells per glomerular cross section at day 6, the
ER4G rats 6.8 3.0 cells and the ER4A receiving group showed
0.4 0.6 proliferating cells per glomerular cross section (Fig. 7).
Furthermore, biopsies of ER4G rats taken on day I exhibited
platelet influx in the glomerular capillary space in contrast to the
ER4A rats (data not shown).
Because no detectable influx of inflammatory cells nor comple-
ment activation or proteinuria was detected upon injection of 1
mg/kg of ER4A, and since the amount of ER4A deposited was
less as compared to the ER4G treated rats, higher doses of ER4A
(10 mg/kg body wt) were administered to Wistar rats. Even though
the pattern of mesangial deposition was identical as compared to
the 1 mg/kg dose, no significant changes were identified histolog-
ically and no complement activation or inflammatory cells were
observed in the glomeruli.
Hematuria
The biopsies of all three groups of rats were analyzed quanti-
tatively for erythrocytes in the lumen of renal tubules (Fig. 8). In
both ER4G and ER4A receiving rats a positive staining was
observed on days I and 6, while control rats only showed positive
staining for erythrocytes in the glomerular capillaries. Tn ER4G
injected rats these erythrocytes were visible in tubular protein
casts, representing histological evidence of combined develop-
ment of proteinuria and hematuria. In addition, erythrocyturia
was quantified using dipsticks, a colorimetric test for hemoglobin
[31] and by direct enumeration of RBC in full urine (Table 2). At
day 0
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Macrophages
Fig. 6. Immunofluorescence staining for rat complement C3, macrophages and polymorphonuclear cells (PMN) on kidney tissue obtained from rats one day
after injection of ER4G or ER4A (All, x250).
day I both ER4A and ER4G treated rats exhibited hematuria. As Table 1. Number of intraglomerular macrophages in ER4A, ER4G or
compared to ER4G, ER4A induced less hematuria on day I (on PBS treated rats
average 50 RBc/1.d urine compared to 20 RBC/1id, respectively). - ds 0 da I thy 6This difference was reflected by larger RBC aggregates in lumen —- ______________________ --- _______________________
of renal tubules of ER4G rats on day 1 (Fig. 8). 0.2 0.4
1.0 1.0
0.1 0.4
Number of macrophages per glomcrulus SD in ER4G, ER4A and
PBS treated rats. Macrophages were identified by monoclonal antibody
EDI and quantified 0, I and 6 days after the start of the experiment.
Statistically significant differences (P < 0.05) were obtained between
day 0 and day I for the ER4G group (two-tailed t-test).
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In the present study we demonstrate that ER4A, a mouse IgA
anti-Thy-LI antibody, when infused in rats is able to induee
hematuria. Deposition of IgA in the mesangial area of glomeruli
in humans is a hallmark of IgAN [32, 33]. Complement compo-
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Fig. 7. Rat MCproliJèration on day 6 detected by PCNA staining in kidney sections obtained after treatment of rats with ER4A or ER4G (All, X250). PCNA
positive cells are indicated by arrowheads.
nent C3 codeposition is reported in 4% to 100% of the biopsies of
patients with IgAN [34]. Other immunoglobulins may also be
found in the affected glomeruli: IgG is reported in 45 to 83% of
the biopsies and 1gM in 9 to 66% [34]. However, glomerular
deposition of IgAl alone has also been observed [35]. The
exclusive depositions of IgA are also associated with the occur-
rence of typical symptoms of IgAN such as hematuria [36].
The degree of activation of complement of various species by
mouse IgA is variable. In vitro studies have shown that mouse IgA
immune complexes are able to activate C3-C9 in the mouse and
guinea pig, but not in human serum. Activation of complement
occurred via the alternative pathway of complement as evidenced
by lack of C4 and C2 consumption [37]. In vivo information on the
activation of mouse complement by mouse IgA is limited. Rifai Ct
a! [6] described an experimental model of lgAN in mice. The
deposition in the renal niesangium of mouse IgA containing
immune complexes, generated with polymeric IgA, resulted in
glomerular changes in mice and a mild proliferative cellular
response in the mesangial area together with hematuria. The
participation of C3 was not essential for the induction of renal
injury, since mice receiving antigen first followed by mouse IgA
shortly thereafter failed to exhibit complement activation in their
glomeruli, despite IgA deposition and similar characteristic his-
tological changes.
The deposition of mouse IgA in the mouse glomerulus depends
on the nature of the antigen [38—40], the route of its presentation
[41], and seems to be under genetic control [42]. Spontaneous IgA
deposition in the kidney has been also demonstrated in the ddY
mouse strain [43]. These mice spontaneously develop anti-histone
auto-antibodies after 40 weeks of age and it is possible that these
auto-antibodies may well contribute to the observed murine
glomerulopathy. Collectively, the experimental evidence clearly
indicates that mouse IgA-IC, formed in vitro or in vivo in either
passive or active systems can deposit in the mesangium [6, 38—42,
44]. Most experimental IgAN models with hematuria also had
complement deposition, whereas the models without hematuria
lacked complement in the affected glomeruli.
Earlier studies by Rits et al have shown that insoluble immune
complexes of MOPC315 are poor activators of rat complement in
vitro, and as compared to complexes prepared with polymeric rat
IgA, at least 100-fold less active [23, 45]. In agreement with these
findings, in the present study administration of mouse IgA
anti-Thy-1.1 antibodies to rats resulted in hematuria without
detectable deposition of C3. it has been hypothesized that the
effector phase of complement, C5-C9 may contribute to renal
injury in IgAN. However, Yoshioka et a! [46] reported on three
patients with primary IgAN with a congenital deficiency in C9.
Both proteinuria and hematuria were found in these patients. IgA
and C3 were deposited predominantly in the mesangial area,
while staining for C9 was negative. Although the clinical course of
the nephritis in these patients is mild and stable, the study
provides evidence that participation of C5b-C9 is not essential for
renal injury. Our studies suggest that induction of hematuria does
not require active participation of complement.
The mechanism by which binding of IgA to the MC, without any
detectable activation of inflammatory mechanisms, leads to he-
maturia is not clear at present. We only observed minimal changes
at the histological level on day 1 in the glomeruli of rats treated
with ER4A without marked MC proliferation or detectable
activation of the coagulation cascade, suggesting low-grade injury
of MC in ER4A treated rats. Clearly the MC in the center of the
capillary tuft can be considered potentially important in the
pathogenesis of GN. Mesangial IC deposition has been associated
with hematuria in the past [47, 48].
Chen and coworkers [49] demonstrated that enhanced glomer-
ular C3 deposition paralleled IgA-IC deposition in proteinuric
mice. Although heavy proteinuria is not a common clinical feature
of IgAN, several studies report on increased incidence of neph-
rotoxic-range proteinuria [50]. This represents a more virulent
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Fig. 8. Light microscopy of kidney sections (day 1) from rats treated with
PBS, ER4G and ER4A, (1-f&E staining, X400). Erythrocytes in the lumen
of renal tubules are indicated by the arrowheads.
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ER4A 10 10—25 20 50 25—80 90
ER4G 50 25—80 50 73 25—80 83
PBS 0 negative 0 (1 negative 0
form of GN with progressive deterioration of renal function and
with more severe histological abnormalities.
Unaltered epitope recognition of the isotype switch variants
was confirmed by reciprocal inhibition analysis. A difference in
intrinsic affinity could be detected between both isotypes. Heavy-
chain class-switching of antibodies may result in different hinge
length and flexibility causing variable reach and rotational adapt-
ability [51]. Furthermore, Brekke et al [52] state that this flexibility
correlates positively with complement fixation and the ability to
reach variably spaced epitopes.
Radiolabel studies with ER4A and ER4G demonstrated that,
despite the difference in affinity, significant amounts of immuno-
globulin were deposited in the glomeruli at a fixed time interval
after injection. In vivo experiments using up to tenfold higher
doses of ER4A also did not induce significant deposition of C3 or
overt inflammation, however, in all cases hematuria was clearly
detected.
We observed that IgA disappears more rapidly from the
glomerulus of rats as compared to ER4G. This may be dependent
on the lower affinity of ER4A for the MC. Immunofluorescence
analysis for the presence of rat 1gM or rat IgG revealed no
positivity either on day 1 nor on day 6. Also when sera obtained on
day 14 from rats receiving either ER4A or ER4G were analyzed
by ELISA for reactivity with ER4A or ER4G no reactivity was
found. These results suggest that a single i.v. dose of these purified
antibodies in the absence of adjuvants does not elicit a significant
antibody response.
In the case of ER4G the disappearance from the mesangial
area may be explained by mesangiolysis; however, in the case of
ER4A we hypothesize that it disappears from the glomerulus by
dissociation due to a lower affinity of the antibody.
In vitro studies showed that binding of ER4A and ER4G to MC
occurs in a dose-dependent fashion and that this binding was
cross-inhibitable, which suggests that the binding of these mono-
clonal antibodies to rat MC is most probably Fc receptor inde-
pendent. Preliminary studies have indicated that the binding of
ER4A to MC is also inhibitable by F(ab')2 fragments of ER4G.
The question is whether or not the mere binding of dimeric IgA to
MC in vivo may lead to mesangial alterations. There is evidence
that binding of ER4G or its F(ab')2 fragments to MC in vitro leads
to apoptosis, suggesting that triggering of MC may occur in the
absence of complement activation [53]. Furthermore, Baker et al
[54] and Shimizu et al [55] independently of each other reported
that MC apoptosis was the major mechanism for resolution of
glomerular hypercellularity in experimental mesangial prolifera-
tive nephritis. Recent unpublished observations by Sato et al
(personal communication) in our laboratory have shown that
dimeric ER4A is also able to induce apoptosis of rat MC in vitro.
In human GN including lupus nephritis and IgAN apoptotic
cells were found in glomeruli. The number of glomerular apopto-
tic cells correlated with the glomerular sclerosis index and dete-
rioration of renal function [56-58]. Taken together apoptosis is, at
least in part, one of the mechanisms of glomerular cell deletion
during progressive glomerular sclerosis. We hypothesize that
subtle morphological changes of rat MC caused by IgA anti-Thy-
1.1 binding may result in altered mesangial homeostatics, result-
ing in anatomical gaps in the GBM through which red blood cells
can escape into the urinary space of the glomerulus and eventually
reach the lumen of the renal tubules [59].
It was reported by Montinaro et al that IL-I as a proinflamma-
tory cytokine induces hematuria in mice treated with IgA contain-
ing IC [601. Furthermore, a higher and more persistent level of
hematuria was achieved by the combination of IL-i with either
IL-6 or INF-y. Since rat MC are able to produce IL-6 in vitro when
incubated with aggregated IgA or IgA-IC [61], we do not exclude
the possibility that cytokines which are released by the affected
MC are participants in the process eventually leading to the
observed injury in the ER4A rats. The precise mechanism respon-
sible for the induction of hematuria by cytokines and IC, however,
still remains unclear and needs further investigation.
It is described that complement fixing anti-Thy-1.1 antibodies
alter the glomerular hemodynamics [62] in rats. In addition data
in rats suggest that in patients with IgAN, urinary thromboxane
levels could predict renal blood flow and that hematuria is best
related to efferent arteriolar constriction, which may be resolved
by perhaps angiotensin antagonists, leading to improved filtration
rate [63]. It will be interesting in this respect to examine how
ER4A deposition in rats alters the glomerular hemodynamics, and
if so, whether a correlation exists with hematuria.
The present studies are of importance because hematuria may
be also found in patients with IgAN without detectable activation
of complement [64]. The present model therefore provides us with
a tool to obtain information about mechanisms leading to hema-
tuna in the absence of complement activation.
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